Please wait while the formulary information is being retrieved.
Drug overview for MYCAMINE (micafungin sodium):
Generic name: MICAFUNGIN SODIUM (MYE-ka-FUN-jin)
Drug class: Antifungals-Systemic
Therapeutic class: Anti-Infective Agents
Micafungin sodium is a semisynthetic, echinocandin antifungal agent.
No enhanced Uses information available for this drug.
Generic name: MICAFUNGIN SODIUM (MYE-ka-FUN-jin)
Drug class: Antifungals-Systemic
Therapeutic class: Anti-Infective Agents
Micafungin sodium is a semisynthetic, echinocandin antifungal agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
MYCAMINE 100 MG VIAL
MYCAMINE 50 MG VIAL
The following indications for MYCAMINE (micafungin sodium) have been approved by the FDA:
Indications:
Acute disseminated candidiasis
Candida peritonitis
Candidal septicemia
Candidemia
Esophageal candidiasis
Prevention of disseminated candidiasis
Professional Synonyms:
Candida species peritonitis
Candida spp. peritonitis
Candidal sepsis
Disseminated candidiasis prophylaxis
Disseminated candidosis prophylaxis
Disseminated moniliasis prophylaxis
Esophageal candidosis
Esophageal moniliasis
Prevention of invasive candidiasis
Septic Candidiasis
Septic Moniliasis
Systemic candidiasis prophylaxis
Indications:
Acute disseminated candidiasis
Candida peritonitis
Candidal septicemia
Candidemia
Esophageal candidiasis
Prevention of disseminated candidiasis
Professional Synonyms:
Candida species peritonitis
Candida spp. peritonitis
Candidal sepsis
Disseminated candidiasis prophylaxis
Disseminated candidosis prophylaxis
Disseminated moniliasis prophylaxis
Esophageal candidosis
Esophageal moniliasis
Prevention of invasive candidiasis
Septic Candidiasis
Septic Moniliasis
Systemic candidiasis prophylaxis
The following dosing information is available for MYCAMINE (micafungin sodium):
Dosage of micafungin sodium is expressed in terms of micafungin.
A loading dose of micafungin is not required.
A loading dose of micafungin is not required.
Micafungin sodium is administered by slow IV infusion. The drug should not be given by rapid IV injection.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| MYCAMINE 100 MG VIAL | Maintenance | Adults infuse 100 mg over 60 minute(s) by intravenous route once daily |
| MYCAMINE 50 MG VIAL | Maintenance | Adults infuse 100 mg over 60 minute(s) by intravenous route once daily |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| MICAFUNGIN 50 MG VIAL | Maintenance | Adults infuse 100 mg over 60 minute(s) by intravenous route once daily |
| MICAFUNGIN 100 MG VIAL | Maintenance | Adults infuse 100 mg over 60 minute(s) by intravenous route once daily |
The following drug interaction information is available for MYCAMINE (micafungin sodium):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Sodium Iodide I 131/Myelosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Sodium iodide I 131 can cause depression of the hematopoetic system. Myelosuppressives and immunomodulators also suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of sodium iodide I 131 with agents that cause bone marrow depression, including myelosuppressives or immunomodulators, may result in an enhanced risk of hematologic disorders, including anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia. Bone marrow depression may increase the risk of serious infections and bleeding.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of sodium iodide I 131 states that concurrent use with bone marrow depressants may enhance the depression of the hematopoetic system caused by large doses of sodium iodide I 131.(1) Sodium iodide I 131 causes a dose-dependent bone marrow suppression, including neutropenia or thrombocytopenia, in the 3 to 5 weeks following administration. Patients may be at increased risk of infections or bleeding during this time. Monitor complete blood counts within one month of therapy. If results indicate leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity.(1) DISCUSSION: Hematologic disorders including death have been reported with sodium iodide I 131. The most common hematologic disorders reported include anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia.(1) |
HICON, SODIUM IODIDE I-131 |
There are 0 moderate interactions.
The following contraindication information is available for MYCAMINE (micafungin sodium):
Drug contraindication overview.
Micafungin is contraindicated in patients with known hypersensitivity to the drug, other echinocandin antifungals (e.g., anidulafungin, caspofungin), or any ingredient in the formulation.
Micafungin is contraindicated in patients with known hypersensitivity to the drug, other echinocandin antifungals (e.g., anidulafungin, caspofungin), or any ingredient in the formulation.
There are 0 contraindications.
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Intravascular hemolysis |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Kidney disease with reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for MYCAMINE (micafungin sodium):
Adverse reaction overview.
Adverse effects reported in 5% or more of patients receiving micafungin include GI effects (diarrhea, nausea, vomiting, abdominal pain, abdominal distention ), pyrexia, infusion-related reactions, hypoglycemia, hypomagnesemia, hypernatremia, hyperkalemia, epistaxis, hematologic effects (thrombocytopenia, neutropenia, anemia), febrile neutropenia, increased AST, increased ALT, increased alkaline phosphatase, rash, pruritus, urticaria, headache, insomnia, anxiety, decreased urine output, hematuria, atrial fibrillation, and tachycardia. Injection site reactions (inflammation, phlebitis, thrombophlebitis) have been reported.
Adverse effects reported in 5% or more of patients receiving micafungin include GI effects (diarrhea, nausea, vomiting, abdominal pain, abdominal distention ), pyrexia, infusion-related reactions, hypoglycemia, hypomagnesemia, hypernatremia, hyperkalemia, epistaxis, hematologic effects (thrombocytopenia, neutropenia, anemia), febrile neutropenia, increased AST, increased ALT, increased alkaline phosphatase, rash, pruritus, urticaria, headache, insomnia, anxiety, decreased urine output, hematuria, atrial fibrillation, and tachycardia. Injection site reactions (inflammation, phlebitis, thrombophlebitis) have been reported.
There are 32 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Hypertension Hypocalcemia Hypokalemia Neutropenic disorder Thrombocytopenic disorder |
Atrial fibrillation Hyperbilirubinemia Hyperkalemia Hypermagnesemia Increased aspartate transaminase |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Acute myocardial infarction Anaphylaxis Anemia Delirium Disseminated intravascular coagulation Hemolytic anemia Hepatic failure Hepatitis Hepatocellular damage Hepatomegaly Injection site sequelae Intravascular hemolysis Jaundice Kidney disease with reduction in glomerular filtration rate (GFr) Pancytopenia Pericardial effusion Renal failure Shock Stevens-johnson syndrome Thrombotic thrombocytopenic purpura Toxic epidermal necrolysis |
There are 20 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Body fluid retention Diarrhea Dyspepsia Fever Flushing Headache disorder Hypotension Nausea Phlebitis after infusion Vomiting |
Chills Hypoglycemic disorder Insomnia Symptoms of anxiety Tachycardia |
| Rare/Very Rare |
|---|
|
Facial edema Pruritus of skin Skin rash Vasodilation of blood vessels |
The following precautions are available for MYCAMINE (micafungin sodium):
Safety and efficacy of micafungin have not been established in pediatric patients younger than 4 months of age. Safety and efficacy of micafungin in pediatric patients 4 months of age and older have been demonstrated based on evidence from adequate and well-controlled studies in adults and pediatric patients and additional pediatric pharmacokinetic and safety data. Although data are limited, some experts state that micafungin can be considered for first-line treatment of invasive candidiasis or for alternative treatment of esophageal candidiasis in children with human immunodeficiency virus (HIV) infection.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. (See Users Guide.) There are no adequate and well-controlled studies of micafungin in pregnant women, and the manufacturer states that the drug should be used during pregnancy only if potential benefits outweigh potential risks to the fetus. In rabbits, administration of micafungin in a dosage about 4 times the recommended human dosage (based on body surface area comparisons) resulted in increased abortions and visceral abnormalities (abnormal lobation of the lung, levocardia, retrocaval ureter, anomalous right subclavian artery, dilatation of the ureter).
Micafungin is distributed into milk in rats; it is not known whether the drug is distributed into milk in humans. Micafungin should be used with caution in nursing women.
Although no overall differences in safety and efficacy were observed between geriatric adults 65 years of age or older and younger adults in clinical trials and other clinical experience has not revealed any evidence of age-related differences, the possibility that some older patients may have increased sensitivity to the drug cannot be ruled out. There are no clinically important differences in the pharmacokinetics of micafungin in healthy adults 66-78 years of age compared with those 20-24 years of age. Dosage adjustments are not necessary when micafungin is used in geriatric patients.
The following prioritized warning is available for MYCAMINE (micafungin sodium):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for MYCAMINE (micafungin sodium)'s list of indications:
| Candida peritonitis | |
| B37.89 | Other sites of candidiasis |
| K65.0 | Generalized (acute) peritonitis |
| T85.71 | Infection and inflammatory reaction due to peritoneal dialysis catheter |
| T85.71xA | Infection and inflammatory reaction due to peritoneal dialysis catheter, initial encounter |
| Candidal septicemia | |
| B37.7 | Candidal sepsis |
| Candidemia | |
| B37.7 | Candidal sepsis |
| Esophageal candidiasis | |
| B37.81 | Candidal esophagitis |
Formulary Reference Tool